NCT00211302View on ClinicalTrials.gov

Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS)

NATerminatedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

February 28, 2006

Study Completion Date

February 28, 2006

Conditions

SchizophreniaSchizoaffective Disorder

Interventions

DRUG

aripiprazole

10-15 mg/day; if needed, dosage may be increased to 30 mg/day after week 2; maintenance 15 mg/day; periodically reassessed

Trial Locations (1)

71103

Psychopharmacology Research Clinic, Shreveport

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Louisiana State University Health Sciences Center Shreveport

OTHER